Boston Scientific sells cardiac surgery and vascular surgery businesses

TriMed Staff | | Health Imaging | Diagnostic Imaging
Boston Scientific has signed a definitive agreement to sell its cardiac surgery and vascular surgery businesses for $750 million to the Getinge Group, a Swedish provider of healthcare equipment and systems. The transaction is expected to close within the next 45 to 90 days, subject to regulatory approvals and customary conditions.

The Natick, Mass.-based company announced its intent to sell the businesses on Aug. 16, as part of its plan to divest non-strategic assets and increase shareholder value.

"This transaction completes a previously announced element of our plan to divest non-strategic assets, focus on our core businesses and increase shareholder value," said Jim Tobin, president and chief executive officer of Boston Scientific. "We deeply appreciate the contributions our cardiac surgery and vascular surgery employees have made to Boston Scientific, our customers and their patients. We know they will continue to serve customers and patients well going forward."

The Getinge Group is a leading global provider of equipment and systems to customers within healthcare, extended care and pharmaceutical industries/laboratories, according to Boston Scientific.

TriMed Staff

Related Content

First human X-rays in space to take place during upcoming SpaceX mission
Mycoplasma pneumonia: Experts highlight imaging findings linked to the pediatric diagnosis
AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.